N Engl J Med April 2010 PMID 20357281

Effect of dutasteride on the risk of prostate cancer.

Gerald L Andriole, David G Bostwick, Otis W Brawley, Leonard G Gomella, Michael Marberger, Francesco Montorsi, Curtis A Pettaway, Teuvo L Tammela, Claudio Teloken, Donald J Tindall, Matthew C Somerville, Timothy H Wilson, Ivy L Fowler, Roger S Rittmaster

Full text PDF Download social card

Mentions

Peak: 8 in May 2023

across 5 sources since Aug 2022

Extended reach

193,929

potential audience

Total likes

4,603

Video views

185,759

Mentions per month

Aug 2022 – Jan 2025

Where it's discussed

X / Twitter9 posts
YouTube5 videos
Blogs5 articles
News4 articles
Facebook2 posts

AI synopsis

What people are saying

Discussions primarily revolve around concerns about conflicts of interest, with posts criticizing the funding sources and author disclosures, such as questions about GSK ownership and consulting fees. The tone indicates skepticism about the study's objectivity, emphasizing the importance of transparency and potential bias, which reduces the perceived impact of the findings on clinical practice.

AgreementLow agreement

Most discussions critique or express skepticism about the publication, especially highlighting conflicts of interest and potential biases.

InterestModerate interest

The posts demonstrate moderate curiosity, focusing on the article's implications and the clinical debate surrounding dutasteride.

EngagementModerate engagement

Participants engage by referencing specific details like conflicts of interest and the broader influence of commercial interests.

ImpactLow impact

The overall tone suggests the publication's influence is questioned, with concerns about credibility and influence dampening its potential impact.

Abstract in brief

The study found that men taking dutasteride had a significantly lower risk (22.8% reduction) of developing prostate cancer compared to those taking a placebo over four years.
While dutasteride reduced overall prostate cancer incidence, there was an increased occurrence of high-grade (more aggressive) tumors (Gleason scores 8-10) in the dutasteride group during the later years.
Patients on dutasteride experienced fewer cases of acute urinary retention, but there was a higher incidence of cardiac failure compared to the placebo group, indicating some potential cardiac risks.

Read the full abstract

All mentions

Long-Term Safety and Efficacy of Dutasteride for Male Hair Loss

This study assesses the safety, tolerability, and effectiveness of daily dutasteride (0.5 mg) in Japanese men with androgenetic alopecia over 52 weeks. Results indicate significant improvements in hair growth with…

Haircafe · May 19, 2024 72,419 views

Evaluating Finasteride's Impact on Prostate Cancer Outcomes

This video examines the long-term effects of finasteride, a medication for enlarged prostate and hair loss, on prostate cancer mortality. It highlights concerns that while it may reduce some cancer risks, it could be…

Haircafe · Dec 17, 2023 38,676 views

Men's Hormones and Diabetes Risk: Insights on 5-Alpha Reductase Inhibitors

This video explores how steroid 5-alpha reductase inhibitors like dutasteride and finasteride may increase the risk of developing type 2 diabetes in men, based on population studies from the UK and Taiwan. Understand…

Haircafe · Aug 30, 2023 36,104 views

Finasteride's Role in Reducing Atherosclerosis and Lowering Cholesterol

Finasteride, a medication for prostate issues and hair loss, delays atherosclerosis progression in mice and reduces plasma cholesterol levels in men. It decreases inflammation and influences liver function related to…

Haircafe · Jun 20, 2024 23,421 views

Impact of Finasteride on Blood Tests and Hormonal Levels in Men

This video discusses the necessary blood work when taking finasteride, highlighting its effects on serum hormones and implications for male pattern baldness treatment.

Haircafe · Jan 15, 2025 15,140 views

M_K

@Max94Cold · X